国际皮肤性病学杂志    2003 29 (2): 120-123   ISSN: 2096-5540  CN: 32-1880/R   经济学分析在皮肤科中的应用 李建红, 陈树民 山东省皮肤病性病防治研究所, 济南250022 收稿日期 2002-07-12  修回日期 null  网络版发布日期 null 参考文献  [1] Lober CW, Dermatology. Positioned for health care reform. Arch Dermatol, 1996, 132(9):1065-1067. [2] Wintroub BU. Dermatology, the academic medical center, and the new millennium. Arch Dermatol, 1999, 135(10):1264-1265. [3] Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol, 1993, 28(3):422-425. [4] Wolkenstein P, Durand-Zaleski I, Moreno JC, et al. Cost evaluation of the medical management of neurofibromatosis 1:a prospective study on 201 patients. Br J Dermatol, 2000, 142(6):1166-1170. [5] Bergmo TS. A cost-minimization analysis of a realtime teledermatology service in northern Norway. J Telemed Telecare, 2000, 6 (5):273-277. [6] Loane MA, Oakley A, Rademaker M, et al. A cost-minimization analysis of the societal costs of realtime teledermatology compared with conventional care:results from a randomized controlled trial in New Zealand. J Telemed Telecare, 2001,7(4):233-238. [7] Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and costbenefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med, 1992, 116(3):238-244. [8] Chen S, Bayoumi AM, Goldstein MK. Cost-comparison analysis ver sus cost-effectiveness analysis:an important difference. J Am Acad Dermatol, 1999, 41 (6):1050. [9] Ellis CN, Reiter KL, Wheeler JR, et al. Economic analysis in derma tology. J Am Acad Dermatol, 2002, 46(2):271-283. [10] Greenhalgh T. How to read a paper. UK:BMJ publishing Group,1997. 138-149. [11] de Rie MA, de Hoop D, Jonsson L, et al. Pharmacoeconomic evalua tion of calcipotriol (Daivonex/Dovonex) and UVB phototberapy in the treatment of psoriasis:a Markov model for The Netherlands. Derma tology, 2001, 202(1):38-43. [12] Rajagopalan R, Anderson R. Impact of patch testing on dermatology specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat, 1997, 8(4):215-221. [13] Chen S. Shaheen A. Garber A. Cost-effectiveness and cost-benefit a nalvsis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study. Arch Dermatol, 1998, 134(12):1602-1608. [14] Rajagopalan R, Anderson RT, Sarma S, et al. An economic evaluation of patch testing in the diagnosis and management of allergic contact dermatitis. Am J Contact Dermat, 1998. 9(3):149-154. [15] Finlay AY. Coles EC. The effect of severe psoriasis on the quality of life of 369 patients.Br J Dermatol, 1995, 132(2):236-244. [16] Lawson V. Lewis-Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis:the Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998, 138(1):107-113. [17] Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol, 1999, 141 (6):1067-1075. [18] Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quali ty of life:results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001,137 (3):280-284. [19] Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol, 2001. 137(3):352-353. [20] Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making, 1989, 9 (2):142-149. [21] Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol, 1996. 135(1):20-23. [22] Ellis CN. Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol, 2002. 46 (3):361-370. [23] Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA, 1989. 262 (20):2879-2886. [24] Rico MJ. Rising drug costs:the impact on dermatology. Skin Therapy Lett, 2000. 5(4):1-2,5. [25] Vignjevic PM, Hux JE, Fisher BK, et al. Monetary and nonmonetary costs to patients attending an ambulatory dermatology clinic. J Cutan Med Surg, 1999, 3(4):188-192. 通讯作者: